Esperion Therapeutics, Inc. (ESPR)
| Market Cap | 819.46M +305.3% |
| Revenue (ttm) | 418.24M +61.1% |
| Net Income | -7.42M |
| EPS | -0.03 |
| Shares Out | 257.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,090,465 |
| Open | 3.180 |
| Previous Close | 3.190 |
| Day's Range | 3.180 - 3.190 |
| 52-Week Range | 1.100 - 4.175 |
| Beta | 1.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About ESPR
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its product... [Read more]
Financial Performance
In 2025, Esperion Therapeutics's revenue was $403.14 million, an increase of 21.31% compared to the previous year's $332.31 million. Losses were -$22.68 million, -56.17% less than in 2024.
Financial StatementsNews
Esperion Therapeutics Transcript: EGM 2026
Stockholders approved the merger with Essence Parent and the related executive compensation proposal. The meeting confirmed a quorum, followed voting procedures, and will report final results in a Form 8-K filing.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on June 16, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and approved all proposals, including director elections, executive compensation, auditor ratification, and a stock plan amendment. No shareholder questions were received, and the CEO closed with thanks to stakeholders.
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperio...
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Stud...
Esperion Therapeutics Quarterly report: Q1 2026
Esperion Therapeutics has published its Q1 2026 quarterly earnings report on May 8, 2026.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on May 4, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Archimed to take Esperion Therapeutics private in $1.1 billion deal
Investment firm Archimed will take Esperion Therapeutics private for up to $1.1 billion, the companies said on Friday, sending the drugmaker's shares up over 55% in premarket trading.
Esperion to be Acquired by ARCHIMED
Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments
Esperion to Report First Quarter 2026 Financial Results on May 7
ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Significant revenue growth and strategic expansion were highlighted, including the acquisition of Corstasis and the upcoming launch of Enbumyst for heart failure. Updated treatment guidelines and international launches are expected to drive further growth, while pipeline advancements and manufacturing improvements support long-term profitability.
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
NEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the entry into a $50 million royalty fi...
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued...
Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolem...
Esperion Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Strong revenue growth and robust U.S. and international market access are fueling expansion, highlighted by the Corstasis acquisition and a focus on heart failure. The company is leveraging digital marketing, preparing for new guidelines, and advancing a diversified pipeline under Vision 2040.
Esperion Therapeutics Earnings Call Transcript: Q4 2025
Record 2025 results featured 144% revenue growth, strong cash position, and major international expansion. The Corstasis acquisition and upcoming U.S. guideline inclusion are set to accelerate growth and broaden the cardiometabolic portfolio.
Esperion Therapeutics Annual report: Q4 2025
Esperion Therapeutics has published its Q4 2025 annual report on March 10, 2026.
Esperion Therapeutics Earnings release: Q4 2025
Esperion Therapeutics released its Q4 2025 earnings on March 10, 2026, summarizing the period's financial results.